Two Systems, Two Realities: The Limits of Comparing U.S. and Danish Vaccine Policy

As debates over vaccine policy resurface in the United States, Denmark is increasingly cited as a model of restraint and efficiency. With narrower vaccination recommendations and fewer boosters for younger populations, the Nordic country is often held up as proof that a lighter public health touch can still succeed. But health experts on both sides of the Atlantic caution that the comparison is far more complicated than it appears.

At first glance, Denmark’s approach seems appealing. The country scaled back routine COVID-19 vaccinations for younger, low-risk groups earlier than many others, citing high population immunity and stable healthcare capacity. But what is often overlooked is the context behind those decisions — a context fundamentally different from that of the United States.

Denmark’s healthcare system is centralized, universal, and tightly coordinated. Public trust in health authorities is high, vaccination data is tightly integrated across the population, and compliance with public health guidance tends to be strong. These factors allow Danish officials to make finely tuned adjustments with confidence that recommendations will be followed and outcomes closely monitored.

The United States operates under nearly opposite conditions. Its healthcare system is fragmented, access varies widely by income and geography, and public trust in health institutions has eroded in recent years. Rates of chronic illness are higher, and disparities in care remain deeply entrenched. In such an environment, policies that work safely in Denmark could have unintended consequences if applied wholesale in the U.S.

Experts also note that Denmark’s decisions were made after achieving high levels of population immunity through a combination of vaccination and prior infection — a profile that does not uniformly apply across the American population. As a result, reducing vaccine recommendations in the U.S. could disproportionately affect vulnerable groups, including older adults and communities with limited healthcare access.

Public health specialists emphasize that comparing outcomes without acknowledging these structural differences risks oversimplifying complex policy choices. Vaccination strategies, they argue, are not interchangeable templates but adaptive responses shaped by demographics, healthcare systems, and social trust.

In the end, the question is not whether Denmark’s approach is right or wrong, but whether it is transferable. For now, most experts agree the answer is no. The U.S. faces its own unique challenges — and its vaccine policy, however imperfect, must be built around them rather than borrowed from a very different national model.